SCHEMBL3010140

SCHEMBL3010140

O=S(=O)(c1cccc(Cl)c1)C1CCN(c2nc(Cc3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
EPHX2 P34913 2/20 0.40
GAA P10253 1/20 0.37
GRM5 P41594 1/20 0.37
AR P10275 1/20 0.36
SPR P35270 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 2/20 0.35
HTR2A P28223 2/20 0.35
DRD2 P14416 1/20 0.35
HTR2C P28335 1/20 0.35
KCNH2 Q12809 1/20 0.35
CTPS1 P17812 2/20 0.35
CHRM4 P08173 1/20 0.35
GRM2 Q14416 1/20 0.35
GRM3 Q14832 1/20 0.35
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018929 0.93 EPHX2 (0.42) RAB9ASMN1; SMN2EPHX2GAAAR
SCHEMBL3014120 0.93 EPHX2 (0.44) RAB9ASMN1; SMN2EPHX2GAAAR
SCHEMBL3015087 0.93 EPHX2 (0.38) RAB9ASMN1; SMN2EPHX2GAAAR
SCHEMBL3003808 0.91 EPHX2 (0.46) RAB9ASMN1; SMN2EPHX2GAAAR
SCHEMBL3001134 0.90 EPHX2 (0.42) RAB9ASMN1; SMN2EPHX2GAAGRM5
SCHEMBL3000939 0.90 CTSS (0.44) RAB9ASMN1; SMN2EPHX2ARMAPT
SCHEMBL3013963 0.90 KDM1A (0.39) RAB9ASMN1; SMN2EPHX2MEN1ALDH1A1
SCHEMBL3003047 0.89 RAB9A (0.41) RAB9ASMN1; SMN2GAAGRM5MEN1
SCHEMBL3021980 0.89 EPHX2 (0.45) RAB9ASMN1; SMN2EPHX2GAAAR
SCHEMBL3013306 0.88 RAB9A (0.42) RAB9ASMN1; SMN2GAAGRM5SPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885EPHX2 4409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.